Clinical trials in Getafe – page 12

3 191 clinical trials in Getafe, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Getafe at a glance

3 191

clinical trials

Research sites1

Quick filters

3 191 trials in Getafe

Open in trial search

Type 2 diabetes mellitus

Recruiting

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Semaglutide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Parkinson's disease

Recruiting

A Phase II Randomized, Double‑Blind Study of RO7568282 for Safety and Efficacy in Early‑Stage Parkinson’s Disease Patients

Investigational

A Phase II Randomized, Double‑Blind Study of RO7568282 for Safety and Efficacy in Early‑Stage Parkinson’s Disease Patients

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Small cell lung cancer extensive stage

Recruiting

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Siltuximab
Sponsor:Amgen Inc.

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:PIPE-791
Sponsor:Contineum Therapeutics Inc.

Contact Research Centre

Squamous cell carcinoma of skin+2

Recruiting

Efficacy and Safety of Photodynamic Therapy with 5‑Aminolevulinic Acid in Immunosuppressed Patients with Actinic Keratosis and Superficial Basal Cell Carcinoma

Registered drugNo placebo

Efficacy and Safety of Photodynamic Therapy with 5‑Aminolevulinic Acid in Immunosuppressed Patients with Actinic Keratosis and Superficial Basal Cell Carcinoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Aminolevulinic acid
Sponsor:Dra. Elena González Guerra

Contact Research Centre

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Imatinib Mesilate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Daraxonrasib
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Acute myeloid leukaemia+3

Recruiting

Phase 1 Study of JNJ-95804306 in Adults with Relapsed or Refractory AML, Higher‑Risk MDS, CLL and SLL

InvestigationalNo placebo

Phase 1 Study of JNJ-95804306 in Adults with Relapsed or Refractory AML, Higher‑Risk MDS, CLL and SLL

InvestigationalNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Janssen Cilag International

Contact Research Centre

Parkinson's disease

Recruiting

Efficacy of intravenous prasinezumab versus placebo in Parkinson's disease patients with severe GBA mutation: a 104‑week randomized double‑blind study

Registered drug

Efficacy of intravenous prasinezumab versus placebo in Parkinson's disease patients with severe GBA mutation: a 104‑week randomized double‑blind study

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Prasinezumab
Sponsor:Universitaetsklinikum Tuebingen AöR

Contact Research Centre

Ductal adenocarcinoma of pancreas

Recruiting

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:ASP3082
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Chronic myeloid leukaemia

Recruiting

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bosutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Non-small cell lung cancer

Recruiting

A study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo

A study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Infliximab
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Getafe

What the registry says about research in the country

01 Respiratory & Infectious Diseases

Groundbreaking research focusing on pneumococcal disease prevention and treatment of acute respiratory distress syndrome, including innovative vaccine development and therapeutic approaches.

Pneumococcal Vaccines
ARDS Treatment
Community-Acquired Pneumonia

Studies aim to enhance protection against respiratory infections and improve patient outcomes in severe cases.

02 Neurological Disorders

Innovative clinical trials exploring treatments for multiple sclerosis and Menière's disease, focusing on disease modification and symptom management.

MS Treatment Comparisons
Inner Ear Disorders
Neurological Therapeutics

Research aims to improve quality of life and disease management for patients with chronic neurological conditions.

03 Cardiovascular & Renal Studies

Comprehensive research into chronic renal disease, pulmonary embolism, and vascular conditions, evaluating new therapeutic approaches.

Renal Disease Management
Pulmonary Embolism Treatment
Vascular Health

Studies focus on improving outcomes in patients with complex cardiovascular and kidney conditions.

04 Oncology & Specialized Care

Advanced research in prostate cancer treatment and management of vitiligo, exploring innovative therapeutic options.

Cancer Treatment
Dermatological Conditions
Specialized Therapies

Trials aim to develop more effective treatments for both oncological and dermatological conditions.

Back to Spain All countries